Sanofi to review its new eczema drug amlitelimab

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study

J&J eyes $100B in sales amid gains for cancer, immune drugs

Alumis soars as TYK2 drug hits mark in psoriasis trials

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

ADVANCING NOVEL DERMATOLOGY MODALITIES: FROM UNCONVENTIONAL MECHANISMS TO REGULATORY ACCEPTANCE & MARKET DIFFERENTIATION

By anaamado | 15 January 2026